John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, discusses how MMRF ...

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...

Recent survey study of 978 cancer patients and their relatives uncovered reasons behind their willingness, or lack thereof, ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, talks unmet need in ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights the ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...

Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights trial startup timelines and workforce ...

In the Phase I dose escalation portion, which evaluated the combination in participants with small cell lung cancer, the ...

In this video interview, Kimberly Tableman, founder & CEO, ESPERO, highlights how data standards are empowering the use of ...